RE
AKRO

RBC Europe’s Akero Therapeutics AKRO Stock Holding History

RBC Europe’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$2.23K – 645
2021
Q3 		$2.23K Hold
100
– – ﹤0.01% 1117
2021
Q2 		$2.48K Hold
100
– – ﹤0.01% 1103
2021
Q1 		$2.9K Buy
+100
New +$3.03K ﹤0.01% 1046

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RBC Europe's AKRO Position: Q4 2021 in Review

RBC Europe sold out of Akero Therapeutics (AKRO) in Q4 2021, closing a stake of 100 shares — an estimated $2.23K sold.

RBC Europe first reported a position in AKRO in Q1 2021 and held it in 3 quarters. The position peaked at $2.9K in Q1 2021. 97 funds tracked by Wall St. Rank hold AKRO as of Q4 2021.

  • RBC Europe reported no remaining Akero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 100 Akero Therapeutics shares in Q4 2021, an estimated $2.23K.
  • RBC Europe first reported a position in Akero Therapeutics in Q1 2021 and held it in 3 quarters.
  • RBC Europe's Akero Therapeutics position peaked at $2.9K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.